ABSTRACT Addition of roxarsone can significantly improve the growth of broiler chickens (Gallus gallus domesticus). Nevertheless, this application will lead to the contamination of the environment as well as animal products. Understanding the response of genes to roxarsone may bring about the discovery of new, safer substitutes. In this study, we monitored the expression of 8,935 genes in chicken breast muscle using microarrays. Analysis showed that 30 genes, such as the interleukin 3 regulated nuclear factor (NFIL3), the regulatory factor X-associated ankyrin-containing protein (RFXANK), the cleavage and polyadenylation-specific factor 3 (CPSF3), and the FK506 binding protein 9 (FKBP9), have consistently up or downregulated (fold change ≥1.5 or ≤0.6, P < 0.05, false discovery rate ≤0.05) throughout the medication periods. The results from microarray analysis were validated by real-time quantitative PCR. Further functional investigation showed that 13 of the identified genes are well documented, and surprisingly, 11 (85%) of these are related to immunity (5 are immunity and defense related, 4 are immunodeficiency disease related, 2 are immunosuppressive drug related), and the remaining 2 are energy metabolism related. These findings may suggest that supplement of roxarsone can improve the immunity of chickens through regulating the expression of associated genes, and as a result contribute to the growth promotion. Further research on the encoded proteins of the differentially expressed genes should provide more evidence for the potential mechanism.
INTRODUCTION
Roxarsone, also known as arsenic 3-nitro-4-hydroxyphenylarsonic acid, has been widely used as an additive to promote animal growth (Kowalski and Reid, 1975; McDougald et al., 1992) . However, the application of roxarsone will not only increase the arsenic residue in animal products but also cause environmental contamination (Garbarino et al., 2003; Stolz et al., 2007) , and as a result potentially jeopardize the health of human beings (Jones, 2007; Vahidnia et al., 2007) . Understanding the response of genes to roxarsone may enable discovery of a new, safer substitute.
In humans, arsenic can inhibit the mitochondrial energy-linked functions, change the metabolism of glucose, carbohydrates, lipids, proteins and bone, and consequently affect immunity, growth, and development (Vahidnia et al., 2007) . In animals, the arsenic compound roxarsone can enhance the immunity of organisms and then contribute to the control of coccidiosis (McDougald et al., 1992) . These studies have provided some clues in understanding the role played by roxarsone in promoting animal growth; however, more work should be performed to fully elucidate this mechanism.
An earlier study has shown that roxarsone can significantly (P < 0.05) improve the growth performance of broiler chickens (Gallus gallus domesticus), and a few genes have been found to have altered expression in the liver in response to roxarsone supplement (Li et al., 2011b) . To further explore the effect of roxarsone on gene expression, we investigated the expression of 8,935 genes in chicken breast muscle.
MATERIALS AND METHODS

Treatment of Broiler Chickens
Animals used in this study conformed to the guidelines for care and use of experimental animals estab-lished by the Ministry of Agriculture of China. The treatment of chickens has been described (Li et al., 2011b) . Briefly, 56 male chickens were evenly allotted into 2 groups and were placed in individual cages with uniform temperature and light conditions. The first group (n = 28) was set as a control without medication, and the second group (n = 28) was treated with 45.4 mg/kg of roxarsone. At the end of wk 4, 5, 6, and 7, six birds were randomly selected from each group and slaughtered through cervical dislocation. The right part of breast muscle was sampled for arsenic residue test, and the left part was taken for gene expression analysis.
Total Arsenic Measurement
Total arsenic was determined by using the hydride generation atomic absorption spectrometry. The collected tissue sample (10 to 50 g) was digested by addition of 6 mL of HNO 3 and HClO 4 (5:1) mixture, heated at 80°C for 45 min in a sand beaker until completely digested. Four percent NaBH 4 was added to convert the inorganic arsenic, arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid to the volatile arsines. And then deionized water was added to a final volume of 25 mL. Arsenic standard solution (1 mg/ mL) purchased from China National Standard Material Center (Beijing, China) was diluted for making a standard curve. Total arsenic was measured at a wavelength of 193.7 nm by using the SOLAAR-M6 atomic absorption spectrometer (ThermoScientific, Wilmington, MA). All samples were analyzed in triplicate. Data were analyzed using Duncan's multiple range test procedure of SAS (SAS Institute Inc., Cary, NC), and a level of 95% significance was considered. The variation between samples is expressed as mean ± SEM.
Preparation of cDNA Microarrays
The cDNA microarrays were prepared as described (Li et al., 2011a) . In brief, the nonredundant expressed sequence tags (EST) identified from 2 cDNA libraries were amplified through PCR reactions. A total of 8,935 fragments were successfully amplified and purified using 96-well Multiscreen Filter plates (Millipore, Billerica, MA). These PCR products were mixed with spotting solution 6 × saline sodium citrate + 3 M betaine to a final concentration between 0.15 to 0.20 mg/ mL, and then printed onto slides (Corning, Lowell, MA) using SpotArray 72 MicroArrays Printing System (PerkinElmer).
Probe Labeling and Hybridization
Total breast muscle RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA). The concentration of RNA was measured by NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific) and the purity was estimated by A260/A280 ratio. The RNA integrity was examined by running on a 0.9% agarose gel and staining with ethidium bromide. Only RNA that showed an A260/A280 ratio between 1.8 and 2.0 and where the band intensity of 28S rRNA was approximately twice that of 18S rRNA was used.
At each time point, 6 samples from the same group were divided into 2 subgroups (n = 3). To reduce the effects of biological variation and experimental cost, equal amount of total RNA from the subgroup was pooled. Twenty micrograms of the total RNA was transcribed into cDNA using oligonucleotide d(T) 18 and Superscript II RT (200 U/µL; Invitrogen) in the presence of 5-(3-)-2′deoxyuridine-5′-triphosphate (aadUTP, Sigma, St. Louis, MO). The aminoallyl-labeled cDNA was then labeled with CyDye using CyDye PostLabeling kit (AmershamPharmacia, Piscataway, NJ). At each time point, the Cy3 (from subgroup 1 of treatment) and Cy5 (from subgroup 1 of control) labeled probes were mixed and hybridized with microarray according to the protocol provided by Corning (http:// www.corning.com). Similarly, a second microarray was hybridized with probes from subgroup 2 of treatment (Cy3 labeled) and subgroup 2 of control (Cy5 labeled). To reduce the potential dye-related bias, dye swap hybridization was also performed. That is, 4 microarrays were hybridized at each time point, and a total of 16 microarrays (from wk 4, 5, 6, and 7) were subjected to analysis.
Microarray Analysis
The hybridized microarrays were scanned using ScanArray 4000 (GSI Group, Bedford, MA) and analyzed using QuantArray 3.0 (Packard BioScience, Meriden, CT). Raw intensity data were imported into GeneSpring 7.2 (Agilent Technologies, Santa Clara, CA) for expression analysis (Li et al., 2011b) . By setting the fold change cut-off values for upregulated genes at ≥1.5 and downregulated at ≤0.6, followed by Mann-Whitney test (P < 0.05) and correction for multiple testing using the Benjamini and Hochberg false discovery rate (FDR ≤ 0.05; Benjamini and Hochberg, 1995) , genes that met with or were greater than these standards at all 4 time points were considered as differentially expressed (DE). The DE genes were analyzed in GenBank (http://www. ncbi.nlm.nih.gov/) and Gene Ontology (http://www. geneontology.org/).
Real-Time Quantitative PCR Validation
Eight genes (4 upregulated and 4 downregulated) were selected for real-time quantitative PCR (RTqPCR) confirmation. Gene-specific primers (Table 1) were designed through Primer3 (http://frodo.wi.mit. edu/). A new batch of total RNA was extracted and pooled in the same way as for microarray analysis. Total RNA was reverse transcribed into cDNA and quantified (Li et al., 2011b) . Housekeeping genes β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as reference genes. At each time point, one replicate and one repeat for each were performed for both treatment and control groups. The target genes were normalized to the average C t value of β-actin and GAPDH, and the mean of 2 −∆∆Ct was used to determine the fold changes. Fold change was presented as the arithmetic mean of the replicates.
RESULTS
Arsenic Residue in the Breast Muscle
Total arsenic in breast muscle was measured using hydride generation atomic absorption spectrometry. The detection limit of this method was estimated to be 0.01 mg/kg. The recovery ranged from 95 to 104%, averaging 99%, and relative SD is less than 3%.
At the beginning of the experiment (wk 3), the mean (n = 6) total arsenic concentration is 0.01 ± 0.00 mg/ kg in both control and treated samples. In the treated group, the accumulation increased rapidly during wk 4 and 5, and then stabilized at 0.11 ± 0.05 mg/kg. In the control group, the arsenic residue increased slightly from 0.01 ± 0.00 mg/kg to 0.02 ± 0.01 mg/kg throughout the test periods. The analysis also shows that after the medication the arsenic residue in the treated group was significantly (P < 0.05) higher than that of the control ( Table 2) .
Identification of the DE Genes
In this study, a total of 8,935 fragments representing unique genes were amplified and applied for the expression analysis of genes in chicken breast muscle. Raw intensity data from microarray were imported into GeneSpring for further analysis. By setting the fold change cut-off values for up-and downregulated genes at ≥1.5 and ≤0.6, respectively, P < 0.05 and FDR ≤0.05, 30 genes (including 19 upregulated and 11 downregulated) were shown to have changed expression throughout the treated periods (Tables 3 and 4) .
The EST sequences of the DE genes were identified from cDNA library database and then analyzed in GenBank and Gene Ontology. Seventeen upregulated genes such as the cleavage and polyadenylation-specific factor 3 (CPSF3), the ribosomal protein L10a (RPL10A), and the liver type carnitine palmitoyltransferase 1A (CPT1A), and 8 downregulated genes such as the importin 9 (IPO9), phosphodiesterase 7B (PDE7B), and the FK506 binding protein 9 (FKBP9) were reported with functional annotations. Homologous sequences were discovered for upregulated gene (GenBank accession no. FD587611) and downregulated genes (GenBank accession no. FD587618, FD587619, and FD587620); however, their functions have not been reported. One upregulated gene, FD587612, was shown to be novel.
Within the 25 functional annotated genes (17 upregulated and 8 downregulated), 16 (11 upregulated and 5 downregulated) have been classified according to their molecular function and the biological process. These genes are involved in various functions such as signal transduction, metabolism, developmental pro- cesses, cellular immunity, and defense. The remaining 8 upregulated and 6 downregulated genes have yet to be classified. The results of complete bioinformatics analysis were listed in Tables 3 and 4 .
Quantitative PCR Confirmation of Genes
A total of 30 genes (19 upregulated and 11 downregulated) were identified as DE. To validate the results of microarray analysis, 4 upregulated genes, the ependymin-related protein 1 (EPDR1), the SUV420H1 suppressor of variegation 4-20 homolog 1 (SUV420H1), the cAMP-specific cyclic nucleotide phosphodiesterase PDE8A1 (PDE8A1), and the novel gene FD587612, and 4 downregulated genes, the ubiquitin C (UBC), the pyruvate dehydrogenase kinase, isozyme 4 (PDK4), the transmembrane protein 183A (TMEM183A), and the member A of family with sequence similarity 53 (FAM53A) were selected for RT-qPCR confirmation. The abundance of target gene was normalized to the level of housekeeping genes, and the mean fold change (n = 4) was calculated and listed in Table 1 .
DISCUSSION
The arsenic content in chicken breast muscle has been measured. Statistical analysis showed that the application of roxarsone has significantly (P < 0.05) increased the arsenic residue compared with the controls (Table 2 ). The accumulation of arsenic mainly occurred at the beginning of treatment (wk 4 and 5), and then leveled off after 3 wk (wk 6 and 7) of medication. These results may suggest that the arsenic accumulation is dependent on the concentration of the provided roxarsone, and after 3 wk of medication the arsenic reached pharmokinetic equilibrium in the breast muscle.
The arsenic residue reached a highest concentration of 0.11 ± 0.05 mg/kg after 3 wk of treatment, which is still lower than the tolerance of 0.5 mg/kg of the US Food and Drug Administration (FDA, 1996) , indicating that the addition of 45.4 mg/kg of roxarsone may not cause dangerous arsenic residue in chicken breast muscle even without the drug withdrawal period. However, many researchers have demonstrated that the application of roxarsone will increase environmental arsenic (Garbarino et al., 2003; Stolz et al., 2007) , which is eventually associated with many human diseases (Jones, 2007; Vahidnia et al., 2007) . Because of the potential hazard to human health, the application of roxarsone has been banned in many European countries. Moreover, the FDA has also recently announced the suspended sales in the United States (FDA, 2011) , suggesting that the usage of roxarsone should be completely prohibited in the poultry industry.
The pooled RNA strategy has been commonly used in microarray experiments to reduce the biological variation (Kendziorski et al., 2005) tical requirements but also improve efficiency (Peng et al., 2003; Zhang et al., 2007) . To investigate the differential expression between the roxarsone-medicated group and the untreated group, 3 samples from the same group of one time point were pooled. This practice potentially reduced the variation of individuals and lowered the cost of experiments. In addition, a biological replicate and a dye swap replicate for each subgroup at each time point were performed. This design can further decrease the false positive rate. In this study, 30 genes have been revealed to have altered expression in chicken breast muscle throughout the experimental periods (Tables 3 and 4 ) by using the pooled RNA strategy. The confirmation of quantitative PCR further proved that the design of experiment is reliable.
Our previous study has shown that roxarsone can significantly (P < 0.05) improve the growth performance of broiler chickens, and the expression of some genes related to cell growth, immunity/defense and energy metabolism was changed in the liver (Li et al., 2011b) . This study further revealed that 30 genes have altered expression in breast muscle (Tables 3 and 4) . Functional investigation showed that 13 had been researched in-depth.
Among the well-documented genes, the Grb2 associated binder 1 (GAB1), the interleukin 3 regulated nuclear factor (NFIL3) and the member A of C-type lectin domain family 16 (CLEC16A) are immunity and defense related. The GAB1 undergoes tyrosine phosphorylation in response to a variety of growth factors, T-and B-cell antigen receptors (Laramée et al., 2007) , and the expression of this gene is regulated by the invasion of bacteria as well (http://www.genome. jp). This may suggest that GAB1 has functions in improving the immunity of cells against bacteria. The second gene, NFIL3, has been found to be expressed in T cells, natural killer (NK) cells, and mast cell lines, and is responsible for the survival of early B-cell progenitors and enhances cell growth (Ikushima et al., 1997) . Similarly, gene CLEC16A, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, has shown to be expressed in immune cells such as the dendritic cells, the B-lymphocytes and the NK cells, and exerts functions in inflammation and immune response (http://beta.uniprot.org/uniprot/Q2KHT3).
Functional investigation has shown that the NF-κB pathway plays a pivotal role in apoptosis and immune response in mammals (Aguilera et al., 2004) , and the avian hairy and enhancer of split 1 (HES1) plays a role in the NF-κB pathway through IκBα (Aguilera et al., 2004) . And gene, the RAB18, a member of Ras oncogene family, is immunity related (Vazquez-Martinez et al., 2007) . Inferring from the above information, genes HES1 and RAB30 might be involved in immunity and defense as well. The discovery of genes GAB1, NFIL3, CLEC16A HES1, and RAB30 in this study suggests that the supplement of roxarsone can improve the immunity and defense of cells.
Interestingly, 3 other genes, the regulatory factor Xassociated ankyrin-containing protein (RFXANK), the CPSF3 and the UBC, were shown to be associated with immunodeficiency disease. The RFXANK, a component of the enhanceosome of major histocompatibility class II (MHC-II), plays a central role in binding of the complex to the promoters of MHC-II genes. Aberrant expression of this gene is associated with the immunodeficiency diseases (Masternak et al., 1998) . The second gene, CPSF3, also known as the premRNA 3′-end-processing endonuclease in RNA polyadenylation, exerts transcriptional activities for both viral and cellular gene expression. The HIV-1 virus protein can specifically increase the expression of CPSF3 (Calzado et al., 2004) . And the third gene, UBC, has also been described to play important immunoreactivity for the release of HIV-1 (Gottwein et al., 2006) .
Our previous study has shown that importin α 3 (KPNA3) and importin α 4 (KPNA4) had altered expression in response to roxarsone supplement (Li et al., 2011b) . Both of these genes have been reported to be functionally related to HIV-1 (Gottwein et al., 2006 ). In the current study, IPO9, another member of the importin family, was found to be DE. Because it is a member of the importin family, we may suppose that this gene may have similar functions in regulating the expression of HIV-1. The discovery of the DE genes RFXANK, CPSF3, UBC, and IPO9 suggests that supplement of roxarsone has also modified the immunity of organisms through the HIV-1 virus pathway.
Unexpectedly, 2 genes, RPL10A and the FKBP9, are found to be immunosuppressive drug related. The RPL10A, a component of the 60S subunit of ribosomes, has been used in immunotherapy for HLA-A26 + cancer patients (Koga et al., 2003) . The expression of RPL10A is regulated by the immunosuppressive drug cyclosporin-A (Fisicaro et al., 1995) . Gene FKBP9, a member of the FK506-binding proteins (FKBP) family, is the target of immunosuppressive drug FK506 (Nishigaki et al., 2002) , which is mainly used to block the activation of T-cells and reduce the activity of the immune system (Yamamoto-Yamaguchi et al., 2001) . The discovery of RPL10A and the FKBP9 further suggests that roxarsone has changed the immunity of the organism even though additional study is needed.
Overall, 11 of the 13 (85 percent) well-documented genes are related to cell immunity and defense, immunodeficiency diseases and immunosuppressive drugs, respectively, and the remaining 2, CPT1A and PDK4, are energy metabolism related. In comparison, 4 genes, the complement component 8 β polypeptide (C8B), the aconitase 1 (ACO1), the importin α 3 (KPNA3), and the importin α 4 (KPNA4), accounting for 50% (4 out of 8) of the well-researched genes in liver, are also immunity related (Gallay et al., 1997; Parker and Sodetz, 2002; Gail et al., 2004; Slade et al., 2006; Li et al., 2011b) . These discoveries may indicate that immunityassociated genes are mainly stimulated and are responsible for growth promotion.
In conclusion, our study has proved that the addition of roxarsone will significantly improve the growth of broiler chickens and this practice is accompanied with the increase of arsenic residue in breast muscle. Globally expression analysis of genes in chicken breast muscle revealed that roxarsone has primarily modified the expression of immunity-associated genes, which may suggest that providing of roxarsone can improve the immunity of animals and consequently contribute to growth promotion. Further research on the DE genes should provide more evidence for the potential mechanism.
